Skip to content

Ozempic & Wegovy Generics in India: 2026 Price Guide

November 12, 2026
Insulin injection pen and diabetes medication box, representing generic semaglutide drugs now sold in India

Medicine & Healthcare

By TrendScope Daily Team · November 12, 2026

Share WhatsApp Facebook X LinkedIn Copy Link

Generic semaglutide — the molecule behind Novo Nordisk’s Ozempic and Wegovy — now costs roughly 70–90% less in India than the original brands, after its core patent expired here in March 2026. At least seven Indian drugmakers, from Dr. Reddy’s to Sun Pharma, now sell their own versions priced from about ₹220 a shot to ₹4,200 a month, against Wegovy’s ₹10,850–₹16,400.

Why Ozempic and Wegovy Suddenly Got Cheaper

Semaglutide, the GLP-1 drug that made Ozempic (for diabetes) and Wegovy (for weight management) global household names, lost patent protection on its core molecule in India in March 2026. Within weeks, at least half a dozen Indian pharma companies — Sun Pharma, Dr. Reddy’s, Zydus Lifesciences, Torrent, Glenmark, Alkem and Eris Lifesciences, along with Natco Pharma — had launched their own injectable versions. Analysts at CareEdge expect prices to fall a further 40–50% in the 2027 financial year as more than 40 companies prepare to enter the market with over 50 branded generics.

The scale of the price collapse is the real story. A therapy that cost upwards of ₹10,000 a month as Novo Nordisk’s branded Wegovy is now available from some generic makers for as little as ₹220 a single shot. That is part of a wider reset in India’s weight-loss drug market that our earlier report on India’s weight-loss drug boom outrunning its own regulators covered from the oversight side — this piece focuses on what each brand actually costs today.

What Each Brand Actually Costs

Prices vary widely by brand, formulation (injectable pen/vial versus oral tablet) and dose. Here is a snapshot of what has been publicly reported so far:

Brand (Maker)FormApprox. PricePrimary Use
Wegovy (Novo Nordisk)Injectable pen₹10,850–16,400/monthWeight management
Ozempic / Rybelsus (Novo Nordisk)Injectable pen / tabletNot stated (branded, premium-priced)Type 2 diabetes
Obeda (Dr. Reddy’s)Oral tablet (3/7/14 mg)₹99 / ₹135 / ₹225 per tabletType 2 diabetes
Sematrinity & Noveltreat (Sun Pharma)Injectable vial₹750–2,000/monthDiabetes & weight management
Generic tablet (Sun Pharma, new)Oral tablet (3/7/14 mg)Not yet announcedType 2 diabetes
Sundae (Eris Lifesciences)Injectable vialFrom ₹220/shot (₹1,290/month)Diabetes & weight management
Generic injectable (Zydus Lifesciences)Reusable injectable pen₹2,200/month (avg.)Type 2 diabetes
Prices as reported in Indian pharma trade press between March and November 2026 (Business Today, Deccan Herald); generic pricing is moving fast, so confirm the current rate with your pharmacist.

“Our endeavour is to provide a high-quality, affordable therapy to a wider patient community in India.”

— Kirti Ganorkar, Managing Director, Sun Pharma

A New Pill Joins Dr. Reddy’s Obeda

The newest development: on November 1, 2026, India’s drug regulator, the CDSCO, cleared Sun Pharma to make and sell its own oral semaglutide tablet, in the same 3 mg, 7 mg and 14 mg strengths as Novo Nordisk’s Rybelsus, for treating type 2 diabetes. It will be made at Sun’s Kamrup, Assam plant, with the active ingredient sourced from a Chinese API maker. Sun’s tablet joins Dr. Reddy’s Obeda, which launched earlier in 2026 as India’s first oral semaglutide generic, after Torrent won a Delhi High Court ruling that its own oral formulation did not infringe Novo Nordisk’s separate patent covering the pill form specifically (the core molecule patent and the oral-tablet patent are two different things in India).

Tablets matter because many patients find a once-daily pill easier to stick with than a once-weekly injection, even though the clinical dose and effect are broadly similar. Sun Pharma has not yet announced a price for its new tablet; Dr. Reddy’s Obeda, the existing oral option, is priced per tablet rather than per month, which can work out cheaper or costlier than the injectables above depending on the dose a patient needs.

Diabetes Drug, Not a Weight-Loss Shortcut

Every one of these approvals, old and new, is for type 2 diabetes management — not a general weight-loss licence. Only Novo Nordisk’s Wegovy and Sun Pharma’s Noveltreat currently carry a specific weight-management indication in India; the rest are diabetes drugs that happen to cause weight loss as a side effect, which is a different regulatory and medical question. India’s Health Ministry has separately flagged that these GLP-1 drugs are increasingly being sold through pharmacies, online platforms and wellness clinics without a prescription for weight loss alone — a practice our earlier coverage on regulators struggling to keep pace with the GLP-1 boom examined in detail. These are prescription medicines with real side effects, meant to work alongside diet and exercise, not instead of them, and a doctor needs to confirm a patient actually needs one before it is started.

There is also a separate safety question that has nothing to do with price: a 2026 study flagged a rare vision-loss risk associated with semaglutide use, which we covered in detail here. Cheaper access does not change the need to be screened and monitored by a doctor while on the drug.

Readers wanting a plain-language primer on how GLP-1 drugs and blood-sugar control actually work may find a book such as The Diabetes Code by Dr. Jason Fung a useful, doctor-written starting point — though it is no substitute for discussing your own treatment with your physician.

This article is for general information and is not medical advice. Please consult a qualified doctor about your own health.

As an Amazon Associate, TrendScope Daily earns from qualifying purchases made through links in this article.

Sources: Deccan Herald, Business Today, Medical Dialogues.

Quick questions

Is generic Ozempic available in India?

Not under the Ozempic brand name itself, but yes in substance: several Indian companies now sell their own approved semaglutide injectables and tablets at a fraction of Novo Nordisk’s price, for the same type 2 diabetes indication.

What is the price of a semaglutide tablet in India?

Dr. Reddy’s Obeda, the first oral generic, is priced at about ₹99 for the 3 mg tablet, ₹135 for 7 mg and ₹225 for 14 mg. Sun Pharma’s newly approved tablet has not announced pricing yet.

Can I buy Ozempic or Wegovy in India without a prescription?

You should not. These are prescription-only medicines, and India’s Health Ministry has specifically warned against buying GLP-1 drugs for weight loss without medical supervision, given real side effects and the need for monitoring.

Related on TrendScope Daily


Bottom line

Semaglutide in India has gone from a premium import to a crowded, fast-cheapening generic market in under a year, with tablets now joining injectables. That is good news for diabetes patients’ wallets — but the drug’s purpose, dosing and monitoring still need a doctor, whatever the price on the label.

Share WhatsApp Facebook X LinkedIn Copy Link